The molecular decision has been a mystery, though we knew it happened.
The heart, long understood as an organ capable of reshaping itself under duress, has now yielded one of its deeper secrets: the molecular logic that determines whether it thickens dangerously or stretches in ways that weaken it. Researchers at the University of Pennsylvania have identified microtubules as the governing switch in this process, and a second pathway — ERK signaling — as the courier that directs growth materials inward, favoring harmful expansion. In naming these mechanisms, science has moved from witnessing transformation to understanding it, and perhaps, one day, redirecting it.
- Heart failure and hypertrophic cardiomyopathy affect millions, yet the molecular instructions driving pathological cardiac reshaping have remained stubbornly hidden — until now.
- Two studies published simultaneously in Science and Science Signaling reveal that microtubule stability acts as a binary switch: stabilized filaments widen heart cells and reinforce their connections, while destabilized ones cause dangerous lengthwise stretching.
- A second discovery shows the ERK signaling pathway acts as a biased courier, delivering growth materials toward the cell's interior and nucleus — a directional quirk that drives the excessive thickening seen in disease, not in healthy exercise.
- FDA-approved drugs already exist that target both microtubules and ERK signaling, but they were built for other purposes and act broadly across the body, making direct repurposing risky without precision delivery to cardiac tissue.
- The field now faces a translation challenge: the mechanism is known, but intervening surgically — affecting only heart muscle cells while sparing everything else — remains the frontier work ahead.
The heart is not a static structure. Under pressure — from disease, hypertension, or chronic stress — it remodels itself, sometimes in ways that sustain life and sometimes in ways that end it. For decades, scientists observed this transformation without understanding the instructions behind it. Two studies published in April in Science and Science Signaling have now mapped the molecular machinery governing how heart cells decide to grow wider or stretch longer.
Researchers at the University of Pennsylvania identified microtubules — the internal scaffolding of heart muscle cells — as a molecular switch at the center of this decision. When microtubules are stable, cells expand in width and their intercellular connections strengthen. When destabilized, cells elongate instead, and those critical junctions weaken. The pattern held consistently across mouse models and human tissue samples. "We didn't expect to find two distinct pathways," said senior researcher Emily Scarborough. Lead author Benjamin Prosser described the discovery as revealing "adjustable targets" for influencing each mode of growth.
A companion finding implicated the ERK signaling pathway — a cellular communication route that delivers the raw materials for growth. The team found that ERK directs these materials inward, toward the nucleus, rather than outward to the cell's edges. This bias promotes width expansion and appears tied specifically to pathological stress, not healthy cardiac adaptation, suggesting it may be a key driver of hypertrophic cardiomyopathy.
The path to treatment is promising but demanding. Many FDA-approved drugs already modulate microtubule stability or ERK activity, but they were designed for other conditions and act across many cell types. Prosser acknowledged the core challenge ahead: any effective therapy would need to reach heart muscle cells specifically, leaving the rest of the body undisturbed. The mechanism has been found. The precision to act on it is the next frontier.
Your heart is not a fixed organ. Under stress—whether from high blood pressure, intense exercise, or disease—it reshapes itself. The walls thicken. The chambers elongate. For decades, scientists knew this happened. They watched it occur in patients and in laboratory models. But they did not know why, or how to stop it when the reshaping turned pathological. Two studies published in April in Science and Science Signaling have now revealed the molecular machinery behind this transformation, opening a path toward controlling conditions like heart failure and dangerous cardiac thickening.
Researchers at the University of Pennsylvania School of Medicine identified that microtubules—structural filaments that form part of the internal skeleton of heart muscle cells—function as a molecular switch. When these microtubules are stabilized, heart cells grow wider. When they become unstable, cells stretch lengthwise instead. This distinction matters profoundly. The team observed the pattern consistently: in mouse models and in samples of human heart tissue, stabilized microtubules not only widened cells but also reinforced the intercalated discs—the critical contact points where muscle cells connect to one another. Destabilized microtubules weakened these connections.
"When we started this research, we didn't expect to find two distinct pathways for the heart to thicken or thin," said Emily Scarborough, a senior researcher in Benjamin Prosser's laboratory. Prosser, a professor of physiology and the study's lead author, emphasized that the molecular decision governing how a heart cell changes size and shape had long remained mysterious. "Now we believe we've discovered adjustable targets for influencing each one."
The second key finding involved the ERK signaling pathway, a common cellular communication route that acts as a delivery system for the building materials heart cells need to grow. The researchers discovered that this pathway preferentially sends these materials toward the cell's interior, near the nucleus, rather than to the cell's outer edges. This directional bias promotes width expansion. As Keita Uchida, an associate researcher in physiology, explained, the growth happens from the inside outward. This matters because excessive thickening of the heart muscle occurs primarily under pathological stress, such as chronic high blood pressure. The ERK pathway is not involved in healthy cardiac growth, which suggests it may be a driver of conditions like hypertrophic cardiomyopathy—a disease in which the heart muscle becomes dangerously thick.
The therapeutic implications are substantial but not straightforward. The FDA has already approved numerous drugs that either stabilize microtubules or modulate ERK signaling. However, these medications were developed for other purposes and affect multiple cell types throughout the body. Repurposing them for heart disease would require precision. "Microtubules and ERK signaling regulate countless biological processes across many different cell types throughout the body," Prosser noted. "We'd probably want to target any therapy more directly to muscle cells to avoid unwanted side effects." The challenge ahead is not discovering the mechanism—that work is done—but learning to intervene with surgical precision, affecting only the heart while leaving the rest of the body untouched.
Citas Notables
When we started this research, we didn't expect to find two distinct pathways for the heart to thicken or thin.— Emily Scarborough, senior researcher
We'd probably want to target any therapy more directly to muscle cells to avoid unwanted side effects.— Benjamin Prosser, professor of physiology
La Conversación del Hearth Otra perspectiva de la historia
Why does the heart need to change shape at all? Why not just stay the same size?
Because stress demands adaptation. When blood pressure rises, the heart works harder. It needs more muscle. But there are two ways to build that muscle—grow wider or grow longer—and they have different consequences for how well the heart actually functions.
And the microtubules are deciding which way to grow?
Exactly. They're like a switch. Stable microtubules say "grow wide." Unstable ones say "grow long." The cell responds accordingly.
But you said wide growth is the dangerous one, in hypertension. So the switch is pointing the wrong direction?
In disease, yes. The ERK pathway is pushing growth inward, toward the nucleus, which favors that widening. In a healthy heart, that pathway stays quiet. But under chronic stress, it wakes up and drives the wrong kind of remodeling.
So if you had a drug that could stabilize or destabilize these microtubules, you could theoretically control which way the heart grows?
In theory, yes. But the problem is those drugs don't know the difference between a heart cell and a cancer cell or a nerve cell. They'd affect everything. You'd need to find a way to whisper the instruction only to the heart.
Is that possible?
That's the next question. The mechanism is solved. The delivery is still a puzzle.